| abstract |
FIELD: medicine. n SUBSTANCE: group of inventions relates to treatment and/or prevention of vestibular disorders. Disclosed is use of a selective antagonist of H4 histamine receptors, selected from a group consisting of 1-[(5-chloro-1H-benzimidazol-2-yl)carbonyl]-4-methylpiperazine, 1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine, 4-((3R)-3-aminopyrrolidin-1-yl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyrimidin-2-ylamine, or cis-4-(piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine for treatment and/or prevention of vestibular disorders and composition for same purpose containing said compounds. n EFFECT: technical result consists in reducing rate of spontaneous nystagmus and reduced excitability of vestibular neurons. n 6 cl, 4 dwg |